| pubmed-article:16153466 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16153466 | lifeskim:mentions | umls-concept:C0278883 | lld:lifeskim |
| pubmed-article:16153466 | lifeskim:mentions | umls-concept:C1517945 | lld:lifeskim |
| pubmed-article:16153466 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:16153466 | pubmed:dateCreated | 2005-9-12 | lld:pubmed |
| pubmed-article:16153466 | pubmed:abstractText | Melanoma is a highly malignant disease that may initially present as a poorly differentiated metastatic tumor. Therefore, the S100 immunostain, immunoreactive in 96% to 99% of melanoma, is used to evaluate poorly differentiated malignant tumors. To develop criteria for correctly diagnosing S100-negative melanomas, we studied the immunohistochemical profile of 1553 patients enrolled in ongoing National Cancer Institute clinical trials for melanoma. Seventeen patients (1%) had metastatic melanoma specimens that were negative for S100. Of the 17 S100-negative lesions, 10 (59%) were immunoreactive for both GP100 and MART-1. Of the 17 S100-negative cases, 13 had a documented primary melanoma. Twenty-four percent of the S100-negative cases had an ocular primary, whereas only 6% of all melanomas had an ocular origin. In 11 of the 17 cases with previous surgical specimens, a prior documented S100-immunoreactive specimen was identified in 9 cases (82%). The time interval for loss of S100 immunoreactivity ranged from 3 weeks to 3 years (average, 13.5 months). There was no association between S100-negative status and histological appearance or site of metastasis. We conclude that all S100-negative melanomas could be correctly identified by negative workup for carcinoma, lymphoma, and sarcoma plus (1) GP100/MART-1 immunoreactivity and/or (2) prior documentation of melanoma. | lld:pubmed |
| pubmed-article:16153466 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16153466 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16153466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16153466 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16153466 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16153466 | pubmed:issn | 0046-8177 | lld:pubmed |
| pubmed-article:16153466 | pubmed:author | pubmed-author:RosenbergStev... | lld:pubmed |
| pubmed-article:16153466 | pubmed:author | pubmed-author:AisnerDara... | lld:pubmed |
| pubmed-article:16153466 | pubmed:author | pubmed-author:BermanDavid... | lld:pubmed |
| pubmed-article:16153466 | pubmed:author | pubmed-author:MakerAjayA | lld:pubmed |
| pubmed-article:16153466 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16153466 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:16153466 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16153466 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16153466 | pubmed:pagination | 1016-9 | lld:pubmed |
| pubmed-article:16153466 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:meshHeading | pubmed-meshheading:16153466... | lld:pubmed |
| pubmed-article:16153466 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16153466 | pubmed:articleTitle | Loss of S100 antigenicity in metastatic melanoma. | lld:pubmed |
| pubmed-article:16153466 | pubmed:affiliation | Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:16153466 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16153466 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16153466 | lld:pubmed |
